Regeneron Dupixent OKd as U.S. 1st New Therapy in Decade for Chronic Spontaneous Urticaria

 Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo

In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment

CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved

https://www.globenewswire.com/news-release/2025/04/18/3064133/0/en/Dupixent-dupilumab-Approved-in-the-U-S-as-the-First-New-Targeted-Therapy-in-Over-a-Decade-for-Chronic-Spontaneous-Urticaria-CSU.html